A Safety, Pharmacokinetic, Single Ascending Dose Study of Tesevatinib in Pediatric Subjects With Autosomal Recessive Polycystic Kidney Disease (ARPKD)
Clinical trial NCT03096080 · COMPLETED
Trial details
- NCT number
- NCT03096080
- Sponsor
- Kadmon Corporation, LLC
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2017-08-24
- Primary completion
- 2019-09-30
- Enrollment
- 10
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.